imagine you have a company that sells candies. You have a big boss that is supposed to lead the company and make sure everybody is doing their job right. But one day, the big boss is no longer there. What happens next? You have to find a new big boss that can do the same job as the old one.

### 7ravenclaw1:
explanation like for 5 years old: So there's a candy shop with a big boss in charge. But one day, the big boss leaves and there is nobody to lead the candy shop. So, they have to find a new big boss to make sure the shop keeps running smoothly. Read from source...

"Sinopharm's vaccine data was cherry-picked, outdated and misleading." "...the Chinese company's fudging of the numbers to manipulate public opinion and make its vaccine appear superior." "The mRNA vaccines by Pfizer and Moderna were highly effective and would have been a better choice."
The author chastised the Chinese government for promoting a substandard vaccine, which has caused the deaths of millions of people.
"It's time for the Chinese government to come clean and admit that their mRNA vaccines were not as effective as they claimed. They should release the full data so that people can make an informed decision about which vaccine to take."
"I have lost all faith in the Chinese government's ability to protect its citizens from the Covid-19 virus. They have shown that they are willing to put their citizens' lives at risk to promote their own agenda."
The author then went on to criticize the Chinese government's response to the Covid-19 pandemic, stating that it had been "completely inadequate."
"The Chinese government's refusal to allow independent investigations into the origins of the virus has only served to fuel conspiracy theories and mistrust."
"The Chinese government's response to the pandemic has been completely inadequate. They have not done enough to protect their citizens from the virus, and they have not been transparent about the data they have collected."
The author then turned their attention to the mRNA vaccines, stating that they were "highly effective" and that people should choose them over the Sinopharm vaccine.
"The mRNA vaccines by Pfizer and Moderna were highly effective and would have been a better choice. They have been shown to be safe and effective in clinical trials and have been approved by regulatory authorities around the world."
"I would recommend that people choose the mRNA vaccines over the Sinopharm vaccine. They have been shown to be safe and effective in clinical trials and have been approved by regulatory authorities around the world."
The author then concluded their article by calling for the Chinese government to release the full data on the Sinopharm vaccine so that people can make an informed decision about which vaccine to take.
"It's time for the Chinese government to come clean and admit that their mRNA vaccines were not as effective as they claimed. They should release the full data so that people can make an informed decision about which vaccine to take."

1. ### David Goubert, President & CEO of Ayr Wellness Resigns

Benzinga by Lipton Tomlins, September 21, 2024

David Goubert has resigned as president and CEO of Ayr Wellness Inc. AYR AYRWF, a Miami-based cannabis multistate operator, after less than a year in the role.

Goubert, who joined the company as president in October of 2022 and took over as CEO in February 2023, is the latest in a series of executive departures at the company, MJBizDaily reported.

The resignation was announced alongside Ayr’s second-quarter earnings report, which revealed a slight dip in earnings and growing net losses.

Ayr's board of directors has initiated a search for a permanent CEO, while Steven Cohen, previously an external legal adviser, will serve as interim CEO.

Are Leadership Changes Enough?

In the second quarter of 2024, the company reported a slight decrease in revenue, down 0.6% from the previous quarter to $117.3 million.

While the MSO managed to reduce its overall expenses, net losses increased to $38 million, a significant jump from the $29 million reported a year earlier.

The company has been attempting to stabilize its financial footing amid these losses. As Goubert explained before his resignation, Ayr was focused on "laying the groundwork for Ayr's next phase of growth."

Interim Leadership

Cohen, who will assume the role of interim CEO, brings a legal and corporate governance background but lacks direct cannabis industry experience. He is a founding member of Blue Raven, a New York-based legal advisory firm specializing in strategic corporate advice and general counsel services.

Cohen's appointment follows another notable departure, Jonathan Sandelman, who stepped down as director and executive chair in July, marking the second high-profile exit within just a few months.

What This Means For Investors

Ayr’s leadership upheaval continues to affect the company's performance.

With the recent executive departures and a lack of experience among the interim leadership, there are concerns that Ayr’s growth prospects may be hampered in the short term.

However, it's worth considering that the company has managed to stabilize its financial situation amidst ongoing challenges. The focus on cutting expenses and improving operational efficiency could help Ayr maintain its market position and eventually bounce back from recent losses.

The search for a permanent CEO is a crucial step in reestablishing stability within the company. Investors will

AI carefully selects each stock and assigns a Score. Each Score is based on an analysis of the underlying company's operations, industry trends, and macroeconomic indicators. The Score is a valuable tool for investors, helping to guide them in their decision-making process.